← HCA Healthcare, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $2.9b $2.2b $3.8b $3.5b $3.8b $7.0b $5.6b $5.2b $5.8b $6.8b
Net Income (Loss) Attributable to Noncontrolling Interest $542.0m $527.0m $602.0m $640.0m $633.0m $765.0m $1.2b $849.0m $897.0m $998.0m
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $3.4b $2.7b $4.4b $4.1b $4.4b $7.7b $6.8b $6.1b $6.7b $7.8b
Amortization of Debt Issuance Costs $34.0m $31.0m $31.0m $30.0m $30.0m $27.0m $29.0m $35.0m $35.0m $44.0m
Amortization of Debt Issuance Costs and Discounts — — — — — $27.0m $29.0m $35.0m $35.0m $44.0m
Amortization of Intangible Assets — — — — — $25.0m $44.0m $20.0m $16.0m $12.0m
Depreciation $1.9b $2.1b $2.3b $2.6b $2.7b $2.8b $2.9b $3.1b $3.3b $3.5b
Depreciation, Depletion and Amortization $2.0b $2.1b $2.3b $2.6b $2.7b $2.9b $3.0b $3.1b $3.3b $3.5b
Goodwill, Impairment Loss $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Share-based Payment Arrangement, Noncash Expense $251.0m $270.0m $268.0m $347.0m $362.0m $440.0m $341.0m $262.0m $360.0m $401.0m
Share-based compensation $251.0m $270.0m $268.0m $347.0m $362.0m $440.0m $341.0m $262.0m $360.0m $401.0m
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property $23.0m $8.0m $428.0m $18.0m ($7.0m) $1.6b $1.3b ($5.0m) $14.0m $37.0m
Gain (Loss) on Extinguishment of Debt ($4.0m) ($39.0m) ($9.0m) ($211.0m) ($295.0m) ($12.0m) ($78.0m) $0 $0 —
Income (Loss) from Equity Method Investments $54.0m $45.0m $29.0m $43.0m $54.0m $113.0m $45.0m $22.0m $23.0m $78.0m
Income Tax Expense (Benefit) $1.4b $1.6b $946.0m $1.1b $1.0b $2.1b $1.7b $1.6b $1.9b $2.0b
Operating Lease, Expense — — — $389.0m $447.0m $478.0m $484.0m — — —
Changes in operating assets and liabilities:
Additional Financial Items
Accounts payable and accrued expenses $144.0m $374.0m $698.0m $396.0m $1.3b $999.0m ($296.0m) $604.0m $359.0m $666.0m
Accounts receivable ($3.2b) ($4.6b) ($423.0m) ($326.0m) $327.0m ($962.0m) ($797.0m) ($935.0m) ($799.0m) ($94.0m)
Acquisition of hospitals and health care entities ($576.0m) ($1.2b) ($1.3b) ($1.7b) ($568.0m) ($1.1b) ($224.0m) ($635.0m) ($266.0m) ($397.0m)
Change in investments $64.0m ($73.0m) $57.0m $25.0m ($20.0m) ($117.0m) $14.0m ($112.0m) ($115.0m) $72.0m
Gain (Loss) Related to Litigation Settlement $246.0m — — — — — — — — —
General and Administrative Expense $373.0m $373.0m $344.0m $370.0m $416.0m $400.0m $378.0m $315.0m $421.0m $548.0m
Income tax payments, net $1.3b $1.2b $872.0m $849.0m $1.0b $2.2b $1.2b $1.4b $1.8b $1.7b
Income taxes $123.0m $433.0m $74.0m $250.0m $41.0m ($70.0m) $571.0m $229.0m $22.0m $310.0m
Increase (Decrease) in Accounts Receivable $3.2b $4.6b $423.0m $326.0m ($327.0m) $962.0m $797.0m $935.0m $799.0m $94.0m
Interest payments $1.7b $1.7b $1.7b $1.9b $1.6b $1.5b $1.7b $1.9b $1.9b $2.2b
Inventories and other assets ($112.0m) ($69.0m) ($242.0m) ($158.0m) ($304.0m) ($540.0m) ($59.0m) ($126.0m) $334.0m ($154.0m)
Losses (gains) on sales of facilities ($23.0m) ($8.0m) ($428.0m) ($18.0m) $7.0m ($1.6b) ($1.3b) $5.0m ($14.0m) ($37.0m)
Net change in short-term borrowings and revolving credit facilities ($110.0m) $760.0m ($640.0m) ($560.0m) ($2.5b) $2.8b $120.0m ($1.0b) ($1.9b) $2.2b
Other ($98.0m) ($45.0m) ($248.0m) ($142.0m) ($205.0m) ($284.0m) ($212.0m) ($246.0m) ($277.0m) ($185.0m)
Revenue from Contract with Customer, Including Assessed Tax — — $46.7b $51.3b $51.5b — — — — —
Sales of hospitals and health care entities $26.0m $25.0m $808.0m $61.0m $68.0m $2.2b $1.2b $193.0m $328.0m $269.0m
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax ($69.0m) ($13.0m) $8.0m $14.0m ($19.0m) — — — — —
Net Cash Provided by (Used in) Operating Activities $5.7b $5.4b $6.8b $7.6b $9.2b $9.0b $8.5b $9.4b $10.5b $12.6b
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $2.8b $3.0b $3.6b $4.2b $2.8b $3.6b $4.4b $4.7b $4.9b $4.9b
Payments for (Proceeds from) Other Investing Activities ($6.0m) $4.0m ($60.0m) ($34.0m) $38.0m $4.0m $21.0m $19.0m $5.0m ($12.0m)
Net Cash Provided by (Used in) Investing Activities ($3.2b) ($4.3b) ($3.9b) ($5.7b) ($3.4b) ($2.6b) ($3.4b) ($5.3b) ($4.9b) ($5.0b)
Cash flows from financing activities:
Issuances of long-term debt $5.4b $1.5b $2.0b $6.5b $2.7b $4.3b $6.0b $3.2b $7.5b $8.5b
Payment of debt issuance costs ($40.0m) ($26.0m) ($25.0m) ($73.0m) ($35.0m) ($38.0m) ($53.0m) ($31.0m) ($67.0m) ($79.0m)
Proceeds from Issuance of Long-term Debt $5.4b $1.5b $2.0b $6.5b $2.7b $4.3b $6.0b $3.2b $7.5b $8.5b
Repayment of long-term debt ($4.5b) ($753.0m) ($1.7b) ($5.3b) ($3.4b) ($3.9b) ($2.8b) ($909.0m) ($2.4b) ($7.4b)
Repayments of Long-term Debt $4.5b $753.0m $1.7b $5.3b $3.4b $3.9b $2.8b $909.0m $2.4b $7.4b
Payments for Repurchase of Common Stock $2.8b $2.1b $1.5b $1.0b $441.0m $8.2b $7.0b $3.8b $6.0b $10.1b
Repurchase of common stock ($2.8b) ($2.1b) ($1.5b) ($1.0b) ($441.0m) ($8.2b) ($7.0b) ($3.8b) ($6.0b) ($10.1b)
Distributions to noncontrolling interests ($434.0m) ($448.0m) ($441.0m) ($542.0m) ($626.0m) ($749.0m) ($1.0b) ($640.0m) ($711.0m) ($827.0m)
Dividends paid — — $487 $550 $153 $624 $653 $661 $690 $679
Payment of dividends — $0 ($487.0m) ($550.0m) ($153.0m) ($624.0m) ($653.0m) ($661.0m) ($690.0m) ($679.0m)
Proceeds from (Payments for) Other Financing Activities ($98.0m) ($45.0m) ($248.0m) ($142.0m) ($205.0m) ($284.0m) ($212.0m) ($246.0m) ($277.0m) ($185.0m)
Net Cash Provided by (Used in) Financing Activities ($2.5b) ($1.1b) ($3.1b) ($1.8b) ($4.7b) ($6.7b) ($5.7b) ($4.1b) ($4.6b) ($8.6b)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — $0 ($15.0m) $8.0m $10.0m ($3.0m) ($20.0m) $7.0m ($1.0m) $9.0m
Effect of exchange rate changes on cash and cash equivalents — $0 ($15.0m) $8.0m $10.0m ($3.0m) ($20.0m) $7.0m ($1.0m) $9.0m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — $0 ($230.0m) $119.0m $1.2b ($342.0m) ($543.0m) $27.0m $998.0m ($893.0m)
Cash and cash equivalents at beginning of period $741.0m $646.0m $502.0m $621.0m $1.8b $1.5b $908.0m $935.0m $1.9b $1.0b
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — $502.0m $621.0m $1.8b $1.5b $908.0m $935.0m $1.9b $1.0b
Change in cash and cash equivalents ($95.0m) $86.0m ($230.0m) $119.0m $1.2b ($342.0m) ($543.0m) $27.0m $998.0m ($893.0m)
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $1.7b $1.7b $1.7b $1.9b $1.6b $1.5b $1.7b $1.9b $1.9b $2.2b
Income Taxes Paid, Net $1.3b $1.2b $872.0m $849.0m $1.0b $2.2b $1.2b $1.4b $1.8b $1.7b

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.